HAE HAEMONETICS CORP
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 313143 · Fiscal year ends 04/03
Financial factors as of 2026-09-26 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.1%
TTM net income YoY-38.2%
TTM EPS YoY-33.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR-6.8%
Margins
Gross margin59.6%
Operating margin12.8%
Net margin7.5%
FCF margin21.6%
EBITDA margin20.7%
Returns
ROE11.9%
ROA4.3%
ROIC (approx.)7.3%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets62.7%
Debt / equity1.25x
Current ratio2.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.32x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue3.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-28 | FY20252025-03-29 | FY20242024-03-30 | FY20232023-04-01 | FY20222022-04-02 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.20M |
| Cost of revenue | $546.44M | $611.87M | $617.51M | $553.56M | $487.69M |
| Gross profit | $787.59M | $748.96M | $691.55M | $615.10M | $505.50M |
| R&D expense | $59.77M | $62.72M | $54.44M | $50.13M | $46.80M |
| SG&A expense | $442.42M | $436.79M | $429.78M | $376.68M | $340.14M |
| Operating income | $156.73M | $221.82M | $164.88M | $156.03M | $80.75M |
| Interest expense | $19.30M | $35.90M | $19.50M | $13.00M | $5.80M |
| Pretax income | $128.03M | $212.07M | $151.87M | $141.40M | $63.63M |
| Income tax | $30.72M | $44.39M | $34.31M | $26.00M | $20.25M |
| Net income | $97.31M | $167.68M | $117.56M | $115.40M | $43.38M |
| EBITDA | $268.45M | $337.40M | $262.10M | $249.34M | $178.50M |
| EPS (basic) | 2.06 | 3.33 | 2.32 | 2.27 | 0.85 |
| EPS (diluted) | 2.05 | 3.31 | 2.29 | 2.24 | 0.84 |
| Weighted avg. shares (diluted) | 47.35M | 50.73M | 51.40M | 51.42M | 51.35M |
| Balance sheet | |||||
| Cash & equivalents | $245.44M | $306.76M | $178.80M | $284.47M | $259.50M |
| Receivables | $216.85M | $202.66M | $206.56M | $179.14M | $159.38M |
| Inventory | $306.37M | $365.14M | $317.20M | $259.38M | $293.03M |
| Current assets | $834.88M | $934.98M | $768.90M | $769.72M | $756.03M |
| PP&E, net | $305.76M | $284.05M | $311.36M | $310.88M | $258.48M |
| Goodwill | $656.37M | $604.27M | $565.08M | $466.23M | $467.29M |
| Intangibles | $447.65M | $455.74M | $406.12M | $275.77M | $310.26M |
| Total assets | $2.40B | $2.45B | $2.20B | $1.93B | $1.86B |
| Current liabilities | $282.60M | $578.11M | $300.38M | $251.82M | $442.27M |
| Short-term debt | $5.01M | $303.56M | $10.23M | $11.78M | $214.15M |
| Long-term debt | $1.22B | $921.23M | $797.56M | $754.10M | $559.44M |
| Total debt | $1.22B | $1.22B | $807.79M | $765.89M | $773.59M |
| Total liabilities | $1.60B | $1.63B | $1.24B | $1.12B | $1.11B |
| Shareholders' equity | $796.32M | $820.84M | $959.96M | $818.00M | $749.42M |
| Net debt | $979.14M | $918.02M | $628.99M | $481.42M | $514.09M |
| Shares outstanding | 45.25M | 48.22M | 50.79M | 50.45M | 51.12M |
| Cash flow statement | |||||
| Operating cash flow | $293.22M | $181.72M | $181.75M | $273.06M | $172.26M |
| Capital expenditure | $32.78M | $39.28M | $38.12M | $191.33M | $96.51M |
| Free cash flow | $260.44M | $142.45M | $143.63M | $81.73M | $75.75M |
| Investing cash flow | -$179.55M | -$161.90M | -$322.39M | -$143.79M | -$86.34M |
| Financing cash flow | -$178.46M | $108.82M | $38.16M | -$100.36M | -$15.75M |
| Depreciation & amortization | $111.72M | $115.59M | $97.22M | $93.31M | $97.75M |
| Stock-based compensation | $33.83M | $29.64M | $28.33M | $25.58M | $24.36M |
| Share buybacks | $175.00M | $225.00M | $0 | $75.00M | $0 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.